Technology platforms

Driving the Future of Cell-Based and Biologic Therapies.

At JY BioMed, we are building a diversified portfolio of cell and biologic platforms that address critical areas in oncology, regenerative medicine, and immune modulation. Each technology platform is developed with a commitment to scientific excellence, manufacturing scalability, and global regulatory readiness. Our platforms span a wide range of investigational programs, from advanced immune cell therapies to stem cell-derived exosome products and target biologics. Together, they form the foundation for the next generation of therapies designed to meet areas of high unmet medical need.

DC-based cancer vaccine

Our dendritic cell (DC) vaccine platform focuses on activating the patient’s own immune system to recognize and eliminate tumor cells. By leveraging mature DCs loaded with tumor-associated antigens, this approach aims to initiate robust T-cell-mediated immune responses against cancer.

Image by National Institute of Allergy and Infectious Diseases

Natural Killer (NK)

Natural killer (NK) cells are innate immune effectors capable of recognizing and eliminating tumor and virally infected cells without prior sensitization or MHC restriction. We are advancing both unmodified and engineered NK cell technologies for potential application in oncology, infectious diseases, and immune modulation.

Umbilical Cord-MSC

Our UC-MSC platform explores the regenerative and immunomodulatory properties of mesenchymal stem cells derived from umbilical cord tissue. This program has successfully advanced into Phase 1 clinical evaluation in Taiwan for applications in neurodegenerative diseases.

Gamma Delta T

Gamma delta T cell (GDT) harnesses the innate cytotoxic potential of γδ T cells to target and destroy cancer cells without the need for antigen presentation through MHC molecules. We are developing both unmodified and engineered GDT products for potential use in oncology and immune disorders.

Anti-CEACAM6 ADC

Our anti-CEACAM6 ADC platform utilizes a proprietary heavy chain antibody (HCAb) targeting CEACAM6, a tumor-associated antigen highly expressed in multiple cancers. The antibody is conjugated to a cytotoxic payload to selectively deliver therapy to cancer cells while minimizing off-target effects.

Hair Follicle-MSC

Our HF-MSC platform leverages mesenchymal stem cells isolated from human hair follicles, offering a novel source for regenerative therapies. Research is ongoing to investigate the potential of HF-MSCs in applications such as hair regeneration, wound healing, and tissue repair.

Regulatory Disclaimer

The technologies and therapies described are at various stages of development. Except for the UC-MSC platform currently under Phase 1 clinical evaluation in Taiwan, all other programs remain under preclinical investigation and have not yet been approved for clinical or commercial use.

< Back